RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Aerosol particle design to promote targeting in the respiratory tract
Hickey, A. J., Pena, E., & Maloney Norcross, S. E. (2025). Aerosol particle design to promote targeting in the respiratory tract. European Journal of Pharmaceutical Sciences, 215, Article 107350. https://doi.org/10.1016/j.ejps.2025.107350
The design of pharmaceutical inhalation aerosol particles is determined by the intended application. Efficiency and reproducibility of dose delivery must be considered in terms of the biological determinants of pulmonary drug delivery and the physicochemical and technical determinants of the therapeutic formulation and device. The biological considerations can be divided into disease, pulmonary target, and lung physiology and anatomy, which dictate pulmonary function and lung deposition of aerosols. The physicochemical properties of the drug, alongside those of added excipients, are the foundation of particle structure. Effective delivery of a particle formulation requires an appropriate device, the technical aspects of which influence aerosolization of the formulation. The interface between the biological, formulation, and technical considerations relates to drug potency, target dose, and the ability to modulate efficacy through pharmacokinetics of disposition. Altogether, these determinants must be considered for efficient delivery to the respiratory tract.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
